Effect of Ketamine vs. Active Placebo on Suicidal Ideation in Depressed Inpatients With Major Depressive Disorder or Bipolar Depression.

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

April 30, 2017

Study Completion Date

April 30, 2017

Conditions
Major Depressive DisorderBipolar I DisorderBipolar II DisorderBipolar DepressionSuicidal Ideation
Interventions
DRUG

Ketamine

DRUG

Midazolam

OTHER

Treatment as usual (TAU)

TAU includes any current treatment a patient is receiving from their primary care practitioner. In the major depressive disorder (MDD) group, TAU may include a newly initiated or longstanding antidepressant. In the bipolar depression (BD) group, TAU may include a mood stabilizer such as lithium or valproate that is a first or second line agent as per Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines (Yatham et al., 2013).

Trial Locations (1)

M4N 3M5

Sunnybook Health Sciences Centre, Toronto

All Listed Sponsors
lead

Sunnybrook Health Sciences Centre

OTHER

NCT02593643 - Effect of Ketamine vs. Active Placebo on Suicidal Ideation in Depressed Inpatients With Major Depressive Disorder or Bipolar Depression. | Biotech Hunter | Biotech Hunter